RSV is also a problem in infants ... handing an advantage to Pfizer, which already has data showing Abrysvo is effective and could get a decision from the FDA on that use in August.

AZ is hoping to fill that need with the combination jab whilst also leapfrogging GSK and Pfizer, which earlier this year brought the first RSV vaccines for the over-60s age group to market.

Get dialed in every Tuesday & Friday with quick updates on the world of crypto ...